Halozyme Therapeutics (NASDAQ: HALO) saw its stock surge 6.10% in after-hours trading on Tuesday, following the release of its impressive first-quarter 2025 results and an upward revision of its full-year guidance.
The biotechnology company reported adjusted earnings per share of $1.11 for Q1, significantly beating the analyst consensus estimate of $0.94. This represents a 40.51% increase from the same period last year. Halozyme's quarterly revenue also exceeded expectations, coming in at $264.86 million, a 35.22% year-over-year increase and well above the estimated $230.18 million.
In light of these strong results, Halozyme raised its 2025 financial guidance. The company now expects full-year revenue between $1.2 billion and $1.28 billion, up from its previous forecast. Additionally, Halozyme increased its non-GAAP EPS guidance to a range of $5.30 to $5.70. Further boosting investor confidence, the company announced a new $250 million share repurchase program, signaling management's optimism about Halozyme's future prospects and commitment to enhancing shareholder value.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.